These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860 [TBL] [Abstract][Full Text] [Related]
3. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539 [TBL] [Abstract][Full Text] [Related]
4. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics. Baby S; Shinde SD; Kulkarni N; Sahu B ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1. Kumarasinghe IR; Woster PM ACS Med Chem Lett; 2014 Jan; 5(1):29-33. PubMed ID: 24883177 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors. Li Z; Yuan Y; Wang P; Zhang Z; Ma H; Sun Y; Zhang X; Li X; Qiao Y; Zhang F; Su Y; Song J; Xie Z; Li L; Ma L; Ma J; Zhang Z Eur J Med Chem; 2023 May; 253():115321. PubMed ID: 37037137 [TBL] [Abstract][Full Text] [Related]
11. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Ota Y; Kakizawa T; Itoh Y; Suzuki T Molecules; 2018 May; 23(5):. PubMed ID: 29734782 [TBL] [Abstract][Full Text] [Related]
14. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors. Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456 [TBL] [Abstract][Full Text] [Related]
15. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714 [TBL] [Abstract][Full Text] [Related]
16. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies. Sheikh KA; Iqubal A; Alam MM; Akhter M; Khan MA; Ehtaishamul Haque S; Parvez S; Jahangir U; Amir M; Khanna S; Shaquiquzzaman M Curr Med Chem; 2024; 31(2):152-207. PubMed ID: 36718063 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma. Mills CM; Turner J; Piña IC; Garrabrant KA; Geerts D; Bachmann AS; Peterson YK; Woster PM Eur J Med Chem; 2022 Dec; 244():114818. PubMed ID: 36223680 [TBL] [Abstract][Full Text] [Related]
19. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A). Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942 [TBL] [Abstract][Full Text] [Related]